UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010163
Receipt number R000011886
Scientific Title Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients
Date of disclosure of the study information 2013/03/06
Last modified on 2013/10/10 09:28:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients

Acronym

Aliskiren Combination with Amlodipine on Target Organ Damage: ACAT study

Scientific Title

Effects of Aliskiren and Amlodipine Combination Therapy or High-dose Amlodipine Monotherapy on Ambulatory Blood Pressure in Hypertensive Patients

Scientific Title:Acronym

Aliskiren Combination with Amlodipine on Target Organ Damage: ACAT study

Region

Japan


Condition

Condition

Hypertension

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the additional effects of 150-300 mg aliskiren or 5mg amlodipine on 24-hour ambulatory blood pressure and vascular function in uncontrolled hypertensive patients with 5mg amlodipine monotherapy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Ambulatory blood pressure monitoring (ABPM)
Pulse wave velocity (PWV)

Key secondary outcomes

Clinic BP, home BP, endothelial function (flow-mediated dilatation), plasma renin activity, plasma aldosterone, microalbuminuria, urinary sodium excretion, NT pro-BNP, high-sensitive CRP, high-sensitive troponin-T, cystatin C.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

After 5mg amlodipine monotherapy for 4 weeks run-in period, 150mg aliskiren is added for first 8 weeks, and dose of aliskiren is doubled to 300mg for next 8 weeks.

Interventions/Control_2

After 5mg amlodipine monotherapy for 4 weeks run-in period, dose of amlodipine is doubled to 10mg throughout 16 weeks treatment period.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with clinic or home BP > 140mmHg in systolic and/or > 90mmHg in diastolic (systolic BP > 130mmHg and/or diastolic BP > 85mmHg in case of diabetes), although receiving 5mg amlodipine monotherapy for 4 weeks period or more.

Key exclusion criteria

1) Secondary hypertension
2) Moderate to severe symptom of heart failure (New York Heart Association >class III), fatal arrhythmia
3) A history of stroke, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft within the past 6 months
4) Severe renal dysfunction (eGFR <30ml/min/1.73m2, or serum creatinine >2.0mg/dl)
5) Severe hepatic disease
6) Uncontrolled diabetes (HbA1c >12%)
7) Pregnant women
8) A history of allergy/hypersensitivity to dihydropyridine calcium channel blockers
9) Patients receiving other antihypertensive drugs than amlodipine
10) Patients receiving P-glycoprotein inhibitor
11) Severe dementia
12) Not eligible for this study based on the decision's of a physician

Target sample size

110


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuomi Kario

Organization

Jichi Medical University School of Medicine

Division name

Division of Cardiovascular Medicine, Department of Medicine

Zip code


Address

3311-1, Yakushiji, Shimotsuke, Tochigi

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Jichi Medical University School of Medicine

Division name

Division of Cardiovascular Medicine, Department of Medicine

Zip code


Address


TEL

0285-58-7344

Homepage URL


Email

kkario@jichi.ac.jp


Sponsor or person

Institute

Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical
University School of Medicine.

Institute

Department

Personal name



Funding Source

Organization

Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical
University School of Medicine.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Fukushima Prefectural Miyashita Hospital
Yanai Municipal Heigun Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

福島県立宮下病院 (福島県), 柳井市立平郡診療所 (山口県).


Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 03 Month 05 Day

Last modified on

2013 Year 10 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011886


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name